KUALA LUMPUR, Nov 10 — BOK MARKETING Sdn Bhd, a branch company of BOOKOFF CORPORATION Ltd, has opened 6th Preloved Superstore ‘Jalan Jalan Japan’ (‘JJJ Superstore’) in Rawang.
Having opened the first ‘JJJ Superstore’ at One City, USJ in November 2016, the company expects ‘Jalan Jalan Japan’ to be a place where Malaysians enjoy shopping akin to taking a walk in Japan.
According to a statement, all goods are ‘Preloved’ and imported from Japan.
Parent company ‘BOOKOFF’ is the most famous preloved store operating over 800 stores throughout Japan. It purchases goods from customers at over 400 million pieces annually.
With concepts namely Preloved in Japan (Good Quality); Hargagiler (Crazy Low Price); and Large Stock (Treasure Hunting), each ‘JJJ Superstore’ has about 200,000 pieces stock with wide categories.
This includes apparel, bags, shoes, households, baby goods, toys, sporting goods, musical instruments, ornaments, furniture and accessories.
The superstore provides customers ‘Entertainment’ and ‘Rich life’ as they can enjoy shopping surrounded by Big Mountain of preloved goods. Customers are also able to experience Japanese culture, hearing J-POP music while at the superstore.
Dr. Michelle Hines, Director of Global Cosmetic Research & Innovation at Mary Kay Inc. (Photo: Mary Kay Inc.)
DALLAS, Nov 11 (Bernama-BUSINESS WIRE) — Mary Kay Inc., a decades-long pioneer and innovator in skincare research, recently provided an educational grant to the International Master Course on Aging Science (IMCAS) Academy to fund their highly anticipated webinar on “Office Peels and Home Peels” available to plastic surgeons, dermatologists, industry specialist, and aesthetic practitioners with the goal of continuing their education and improving practice.
The webinar, which debuted worldwide to over 1,200 attendees, is just the latest event from the Academy whose mission is to provide leading education on the topic of aging science.
The webinar, moderated by IMCAS Academy Executive Editor, Dr. Dominique Du Crest, featured a renowned and diverse lineup of speakers from around the world. Mary Kay’s Dr. Michelle Hines, Director of Global Cosmetic Research & Innovation, kicked off the webinar with an overview of chemical peels and then joined experts to discuss various subjects surrounding a number of topics on the agenda. The topics covered the existential question of whether ‘to peel or not to peel’, different types of peels, peeling for darker skin types, the use of new and innovative ingredients, the dangers of peeling for patients with various skin diseases, with speakers also sharing tips on how to prolong the benefits of peeling post-procedure. The session concluded with a robust Q&A panel chaired by Dr. Uliana Gout, M.D. Alongside Dr. Hines, the featured speakers included Dr. Foteini Bageorgou, Dermatologist; Dr. Marina Landau, Dermatologist; and Dr. Mukta Sachdev, Dermatologist.
“Women of any age, anywhere in the world, want flawless skin,” said Dr. Hines. “Currently, chemical peels are a popular skin rejuvenation and skin resurfacing procedure. Professional and at-home peels offer different experiences and benefits. As there are many options available, education and awareness are important to make the best choice. Mary Kay was thrilled to provide a grant to further education and research on the topic.”
“I would like to underscore the dynamic and growing nature of our diverse community,” said Dr. Du Crest. “We have over 28,000 physician members, and with the outbreak of COVID-19, our community has expanded tremendously. Outside of our Congress, we offer webinars, sometimes twice a week, through which we create opportunities for doctors, physicians, dermatologists, and aestheticians all over the world to come together and share knowledge, expertise, and answer industry-related questions from their peers without having to travel or leave their home or office. Our e-Learning platform houses hundreds of clinical cases, numerous blog posts, over 40 webinars annually, and thousands of videos for industry professionals to be able to watch and enrich themselves on demand.”
The webinar was recorded and is available for viewing on the IMCAS Academy Library portal.
About Mary Kay One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company 57 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.
About International Course on Aging Science (IMCAS) IMCAS was established in 1994 in Paris, France, as a congress dedicated to plastic surgeons and dermatologists. Since its inception, IMCAS has sought to bridge the knowledge gap between Plastic and Reconstructive Surgery and Dermatology, thereby generating synergies and helping bridge together these two fields. Its mission is to enable aesthetic practitioners to access quality scientific content on demand. IMCAS recently launched their e-learning platform, IMCAS Academy, which offers its subscribers instant access to instructional videos, scientific papers, expert interviews and more. For more information about IMCAS, click here: https://www.imcas.com/en.
The award selection for the Outstanding Contribution Award of the Peony Capital of China (Heze) 2021 and the Peony Series Awards are launched.
HEZE, China, Nov. 11, 2020 /Xinhua-AsiaNet/–
Heze, a city located in Shandong Province, China, recently launched an award selection for the Outstanding Contribution Award of the Peony Capital of China (Heze) 2021 and the “Blooming World” Peony Series Awards and called for entries for the “Blooming World” Peony Series Competitions from home and abroad, according to the Information Office of the People’s Government of Heze Municipality.
The Outstanding Contribution Award of the Peony Capital of China (Heze) is an honorary award established by the CPC Heze Municipal Committee and the Heze Government to recognize individuals or teams for outstanding contributions to the development of Heze’s peony industry and peony culture and art.
Once a year, up to 2 individuals (teams) are selected and presented with a one-time award of CNY 300,000. Individuals or teams from China and abroad are recognized for their outstanding achievements in the cultivation and breeding, scientific research and development, and business model innovation of peony as well as peony culture and art creation and production, outstanding contributions to the development of Heze’s peony industry and peony culture and art, and great social influence.
In May 2021, Heze will select the winners of the 2nd annual Outstanding Contribution Award of the Peony Capital of China and reward them in a grand ceremony.
The “Blooming World” Peony Series Awards 2021, organized by the Heze Government, includes awards in seven areas under two categories: the peony industry development and the peony culture and art. The peony industry development category includes 3 areas: the Peony Show Competition, the Peony Scientific Innovation, and the Peony Industry Business Model Innovation. The peony culture and art category includes 4 areas: the Peony Themed Art Competition, Calligraphy Competition, Photography Competition, and Cultural Creative Design Competition. Each has a top award dubbed as the “Golden Peony Award” of the Peony Capital of China (Heze) and has a prize of CNY 100,000, in addition to first, the second, the third, and other prizes.
The selection for the Peony Scientific Innovation Award and the Peony Industry Business Model Innovation Award is scheduled in early 2021 while the five competitions, the Peony Show Competition, the Art Competition, the Calligraphy Competition, the Photography Competition, and the Cultural Creative Design Competition are already officially started. For details on the competitions, please visit the official website of the awards at http://heze.dzwww.com/hkss/.
All competitions are open to participants from China and abroad. In addition to reviews by the professional judging panels, the entries for these competitions will be rated by the netizens and the on-site audiences during online and offline exhibitions of the Heze International Peony Cultural Tourism Festival in 2021.
Heze will simultaneously hold a grand festival and a cultural feast for everyone by conducting a series of influential, interesting, and participatory public activities, such as the food selection with the theme of “Seeking Delicious Food in the Capital of Peony”, the Opera Contest for Fans in the Capital of Peony, the “Peony Book Fair” Art Festival, and the Peony Themed Poetry Contest.
Source: The Information Office of the People’s Government of Heze Municipality
Caption: The award selection for the Outstanding Contribution Award of the Peony Capital of China (Heze) 2021 and the Peony Series Awards are launched.
Both cabotegravir and oral FTC/TDF have high efficacy for PrEP among women in sub-Saharan Africa
Durham, N.C., Nov 10 (Bernama-GLOBE NEWSWIRE) — Researchers from the HIV Prevention Trials Network (HPTN) announced today data from the HPTN 084 clinical trial indicate that a pre-exposure prophylaxis (PrEP) regimen of long-acting cabotegravir (CAB LA) injections once every eight weeks was safe and superior to daily oral tenofovir/emtricitabine (FTC/TDF) for HIV prevention among cisgender women in sub-Saharan Africa. During a planned review of study data, an independent Data and Safety Monitoring Board (DSMB) recommended the study sponsor―the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health―stop the blinded phase of the trial and share the results. The study was originally designed to continue through 2022.
NIAID has accepted the DSMB’s recommendations and is releasing the results in the interest of public health. The study investigators will provide more detailed information about the study findings, including more comprehensive data, as soon as is feasible. The HPTN 084 study is jointly-funded through a unique partnership between NIAID, the Bill & Melinda Gates Foundation, and ViiV Healthcare. Study drugs are provided by ViiV Healthcare and Gilead Sciences, Inc.
“The results from HPTN 084 are incredibly important for women in Africa where lowering HIV incidence remains a priority,” said Dr. Sinead Delany-Moretlwe, HPTN 084 protocol chair, director of research at Wits Reproductive Health and HIV Institute, and research professor at the University of the Witwatersrand in Johannesburg, South Africa. “We know that adherence to a daily pill continues to be challenging, and an effective injectable product such as long-acting CAB is a very important additional HIV prevention option for them. We are grateful to the women who volunteered for this study and the research staff, as this study would not have been possible without their commitment to HIV prevention.”
Overall, HPTN 084 enrolled 3,223 cisgender women at research sites in Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda, and Zimbabwe. The average age of study participants was 26 years and 57% of participants were 18-25 years old. Eighty-two percent of the women enrolled were not living with a partner, 55% reported two or more partners in the past month, with 34% having a primary partner who is reported to be living with HIV or having an unknown HIV status. A total of 38 HIV infections occurred during follow-up, with four infections in the CAB LA arm (incidence rate 0.21%) and 34 infections in the FTC/TDF arm (incidence rate 1.79%). The hazard ratio in the CAB LA versus FTC/TDF arm was 0.11 (95% CI 0.04-0.32). Approximately nine times more incident HIV infections occurred in the FTC/TDF arm than in the CAB arm. These results meet the statistical criteria for superiority of CAB LA compared to FTC/TDF in the HPTN 084 study population. The higher-than-expected level of adherence to FTC/TDF throughout the study and overall low incidence rate in both arms of the study clearly demonstrate both drugs were highly effective at preventing HIV acquisition.
“After years of evaluating HIV prevention strategies for women, I am thrilled that we have found CAB LA so effectively reduces HIV acquisition and provides women more choices in how to protect themselves,” said Dr. Mina Hosseinipour, HPTN 084 protocol co-chair, professor of medicine at the University of North Carolina (UNC) at Chapel Hill School of Medicine and scientific director of UNC Project-Malawi in Lilongwe, Malawi.
Earlier this year, the HPTN 083 clinical trial showed that a PrEP regimen containing CAB LA injected once every eight weeks was superior to daily oral FTC/TDF for HIV prevention among cisgender men and transgender women who have sex with men.
“The results from HPTN 084 along with the HPTN 083 results released earlier this year show how far we have come in the fight against HIV,” said Dr. Myron Cohen, HPTN co-principal investigator and director of the Institute for Global Health at the University of North Carolina in Chapel Hill. “A highly effective product like CAB LA that does not require a daily pill can be an important part of ending the epidemic globally.”
“The HPTN is thrilled by these outstanding results, a milestone for the prevention of HIV among women,” said Dr. Wafaa El-Sadr, HPTN co-principal investigator, director of ICAP and professor of epidemiology and medicine at Columbia University in New York. “These findings motivate continued evaluation of the safety of CAB LA in adolescents, a group at substantial risk for HIV infection. Defining the safety of CAB LA in adolescents will hopefully lead to faster access to CAB LA, once approved for use as PrEP.”
About HPTN
The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community members and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. NIAID, NIMH, Office of The Director, and NIDA, all part of NIH, co-fund the HPTN. The HPTN has collaborated with more than 85 clinical research sites in 19 countries to evaluate new HIV prevention interventions and strategies in populations that bear a disproportionate burden of infection. The HPTN research agenda – more than 50 trials ongoing or completed with over 161,000 participants enrolled and evaluated – is focused primarily on the use of integrated strategies; use of antiretroviral drugs (antiretroviral therapy and pre-exposure prophylaxis); interventions for substance abuse, particularly injection drug use; behavioral risk reduction interventions and structural interventions. For more information, visit hptn.org.
Kevin Bokoch HIV Prevention Trials Network (HPTN) +1.440.376.1901 kbokoch@fhi360.org
KUALA LUMPUR, Nov 9 — The Tokyo Metropolitan Government (TMG) will organise Tokyo Sustainable Finance Week in February 2021, to promote ESG investment and sustainable finance that contribute to sustainable cities development and enhance TMG’s presence in these areas.
During the week, the Tokyo Sustainable Finance Forum will be held, targeted at professionals working at financial institutions and relevant organisations in Japan and overseas.
In addition, the Financial Seminar for Tokyo Residents will also be held to improve financial literacy and raise awareness for sustainable finance among the general public.
Programme includes Keynote speech 1: Global Trends in Sustainable Finance (tentative); Keynote speech 2: Development of Sustainable Finance in Japan; and, Keynote speech 3: Sustainable Finance Trends in Japan and Overseas from the Perspective of Investors.
In addition to the keynote speeches, a panel discussion will also be held, according to a statement.
Applications to attend the Tokyo Sustainable Finance Forum are accepted beginning Nov 9, while applications for the Financial Seminar for Tokyo Residents will open in early December.
wonderland 